Nuclear Medicine (Radiopharmaceuticals) Market is geared to grow at a CAGR of 12.5% from 2023 to 2032 | insightSLICE
The market for Nuclear Medicine (Radiopharmaceuticals) was valued at US$ 7.95 billion in 2021 and is projected to grow at a CAGR of 12.5% through 2032.
The report on the Global Nuclear Medicine (Radiopharmaceuticals) Market includes information about market size, product analysis, and projections for the years 2022 through 2032. This report is divided into three sections, with 2020 serving as the historic period, 2021 serving as the base year, and 2022 to 2032 serving as the forecast years.
Access the sample report: https://www.insightslice.com/request-sample/364
The analysis also considers the industry’s competitive environment; as a result, the study contains necessary details and industry forecasts for the top players in the worldwide Nuclear Medicine Market. In addition, the report will include information on important advancements, global and regional sales networks, marketing strategies, technology development objectives, global workforce, and top-level managers for all significant market participants.
The key players of the Global Nuclear Medicine (Radiopharmaceuticals) Market are:
Curium Pharma, Eczacbaş-Monrol, Bayer AG, Cardinal Health, Inc., Advanced Accelerator Applications, GE Healthcare, NTP Radioisotopes SOC Ltd, Lantheus Medical Imaging Inc., Nordion Inc., and The Bracco Group are significant market participants in the global nuclear medicine industry.
What information is provided in this report?
With a focus on every functioning business category, the research provides an in-depth analysis of significant companies having the major share of the worldwide market and would determine the corporate segment concentrating on Nuclear Medicine (Radiopharmaceuticals). This would evaluate the market shares of well-known players in the global Nuclear Medicine (Radiopharmaceuticals) industry. For instance, the three business divisions of Bayer AG are Crop Sciences, Pharmaceuticals, and Consumer Health. The pharmaceuticals business section of the corporation delivers nuclear medicine devices, contributing US$19,337.1 million in revenue in 2019.
Proceed to purchase: https://www.insightslice.com/buy-now/364
The study takes into account essential competitive data from all nuclear medicine enterprises, including corporate strategy, product offerings, key developments, SWOT analysis, and research and innovation targets. The participants involved in the market ecosystem and their contributions will be taken into account in the global nuclear medicine market research. All of the goods in the company’s nuclear medicine business division would be the main emphasis of the product portfolio. Similar to this, the portion of the current development would concentrate on the most recent firm activities, including geographic expansion, mergers and acquisitions, the launch of new products, and strategic partnerships and agreements in the global nuclear medicine market.
Global Global Nuclear Medicine (Radiopharmaceuticals) Market Market Key Segments:
By Product:
- Diagnostic products
- SPECT
- TC-99m
- TL-201
- GA-67
- I-123
- Other SPECT products
- PET
- F-18
- SR-82/RB-82
- Other PET products
- Therapeutic Products
- Alpha Emitters
- RA-223
- Beta Emitters
- I-131
- Y-90
- SM-153
- Re-186
- Lu-117
- Other beta emitters
- Brachytherapy
- Cesium-131
- Iodine-125
- Palladium-103
- Iridium-192
- Other brachytherapy products
- Alpha Emitters
- SPECT
By Application:
- Cardiology
- Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- Others
By End Use:
- Hospitals & Clinics
- Diagnostic Centers
- Others
By Geography:
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Rest of South America
The key players of the Global Nuclear Medicine (Radiopharmaceuticals) Market are:
Curium Pharma, Eczacbaş-Monrol, Bayer AG, Cardinal Health, Inc., Advanced Accelerator Applications, GE Healthcare, NTP Radioisotopes SOC Ltd, Lantheus Medical Imaging Inc., Nordion Inc., and The Bracco Group are significant market participants in the global nuclear medicine industry.
Read more about the report inclusions: https://www.insightslice.com/nuclear-medicine-radiopharmaceuticals-market
Growth of Global Nuclear Medicine (Radiopharmaceuticals) Market :
. Radiopharmaceuticals are used in the complex field of nuclear medicine for detection and diagnosis procedures. The radiopharmaceuticals are utilized for precision medicine, detection-based diagnostics, and therapies and are made of radioisotopes created by particle accelerators like the clinical cyclotron. Scanning and testing instruments have undergone a major evolution due to advancements in medical technology.
Nuclear drugs are becoming more and more well-known around the world as a result of their usage in diagnostic imaging technology to improve the accuracy of diagnosis. The use of radiopharmaceuticals in the management of diseases such as cancer, thyroid, bone metastases, arthritis, and others involve administering ionizing doses of radiation to the areas of the disease for either curative or palliative purposes.
Because they are used in such small doses, nuclear medications and radiopharmaceuticals have no negative side effects. It is projected that these features of radiopharmaceuticals would be a key driver propelling the growth of the global nuclear medicine market throughout the forecast period and will spur the development of improved techniques
Regional performance of Nuclear Medicine (Radiopharmaceuticals) Market
North America led the global nuclear medicine market in terms of market share in 2019 and is expected to continue to do so throughout the forecast period. The incidence of chronic diseases, particularly cancer and cardiovascular disorders, as well as increased investment in the development of novel drugs are the main reasons propelling the expansion of nuclear medicine in North America.
During the projected period, Asia Pacific is expected to develop at the highest rate and contributed a sizeable portion of the worldwide nuclear medicine market in 2019. In the upcoming years, the Asia Pacific nuclear medicine market is anticipated to be driven by rising investments in the development of the biotechnology and pharmaceutical industries as well as rising use of cutting-edge diagnostic and therapeutic solutions.
Related reports:
Global Personal Protective Equipment Market : https://www.insightslice.com/personal-protective-equipment-market
Global Sepsis Diagnostic Market : https://www.insightslice.com/sepsis-diagnostic-market
insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at info@insightslice.com.
Contact us:
Alex R
+1 707 736 6633
Editor Details
-
Company:
- insightSLICE
- Website:
